Pregabalin市場規模、佔有率、成長分析（按劑型、按應用、按藥物類別、按分銷管道、按最終用戶、按地區）- 行業預測，2025 年至 2032 年

2023 年全球Pregabalin市場規模為 19 億美元，預計將從 2024 年的 19.7 億美元成長到 2032 年的 26.6 億美元，預測期內（2025-2032 年）的複合年成長率為 3.8%。

由於癲癇、神經病變疼痛、纖維肌痛和焦慮等神經系統疾病的發生率不斷上升，尤其是在 25-60 歲的成年人中，全球Pregabalin市場正在經歷顯著成長。根據世界衛生組織統計，全世界有超過 5,000 萬人患有癲癇，其中 70% 的人如果得到適當治療可以過上無癲癇發作的生活。成年人仍然是主要的消費群組，因為他們對這些慢性疾病高度敏感。此外，主要企業為改善低收入和服務欠缺地區的藥物取得而做出的策略性努力正在幫助市場擴大。低收入國家約 75-90% 的癲癇患者得不到充分治療，滿足這項未滿足的需求代表著一個巨大的成長機會。不斷成長的目標人口和不斷增加的全球疾病負擔繼續推動對Pregabalin治療的市場需求。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 顧客購買行為分析

Pregabalin市場規模（依劑型分類）及複合年成長率（2025-2032）

• 市場概覽
• 口服膠囊
• 口服溶液
• 口服錠劑
• 緩釋製劑

Pregabalin市場規模（依應用）及複合年成長率（2025-2032）

• 市場概覽
• 癲癇
• 神經病變疼痛
• 焦慮症
• 其他

Pregabalin市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概覽
• 纖維肌痛藥物
• 抗驚厥藥
• 其他

Pregabalin市場規模（依通路分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院藥房
• 零售藥局
• 網路藥局
• 其他

Pregabalin市場規模（依最終用戶分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院
• 專科診所
• 居家護理
• 其他

Pregabalin市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益同比對比（2022-2024 年）

主要企業簡介

• Pfizer Inc.（US）
• GSK plc（UK）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sanofi（France）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Zydus Cadila（India）
• Lupin（India）
• Amneal Pharmaceuticals LLC.（US）
• Cipla Inc.（US）
• Torrent Pharmaceuticals Ltd.（India）
• Aurobindo Pharma Limited（India）
• Glenmark Pharmaceuticals Limited（India）
• Medley Pharmaceuticals Ltd.（India）
• Genesisbiotec（India）
• Biomax Biotechnics（India）

結論和建議

Global Pregabalin Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 1.97 billion in 2024 to USD 2.66 billion by 2032, growing at a CAGR of 3.8% during the forecast period (2025-2032).

The global pregabalin market is witnessing significant growth driven by the rising prevalence of neurological conditions such as epilepsy, neuropathic pain, fibromyalgia, and anxiety, especially among adults aged 25 to 60. According to WHO, over 50 million people suffer from epilepsy globally, with up to 70% potentially living seizure-free if properly treated. Adults remain the dominant consumer group due to their higher susceptibility to these chronic disorders. Additionally, strategic initiatives by key players to improve access in low-income and underserved regions are bolstering market expansion. With around 75-90% of epilepsy patients in low-income countries lacking adequate treatment, addressing this unmet need presents a major growth opportunity. The growing target population and increasing global disease burden continue to fuel market demand for pregabalin therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pregabalin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pregabalin Market Segments Analysis

Global Pregabalin Market is segmented by Forms, Application, Drug Class, Distribution Channel, End User and region. Based on Forms, the market is segmented into Oral Capsule, Oral Solution, Oral Tablet and Extended Release. Based on Application, the market is segmented into Epilepsy, Neuropathic Pain, Anxiety Disorder and Others. Based on Drug Class, the market is segmented into Fibromyalgia Agents, Anticonvulsants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pregabalin Market

The global pregabalin market is being significantly driven by the rising incidence of neuropathic pain and generalized anxiety disorders. Healthcare professionals in both developed and emerging markets are increasingly turning to pregabalin due to its dual therapeutic benefits for managing chronic pain as well as alleviating anxiety symptoms. In 2024, treatment guidelines in countries like Canada and Australia were updated to recognize pregabalin as a first-line option, further enhancing its adoption in both neurological and psychiatric treatments. This growing acceptance among medical practitioners is contributing to an upsurge in pregabalin's utilization worldwide, thereby expanding its market footprint.

Restraints in the Global Pregabalin Market

The global pregabalin market faces significant constraints primarily due to its classification as a controlled substance in many countries, which hampers its market growth. Regulatory restrictions, particularly concerning prescribing practices, stem from concerns about the drug's potential for abuse and dependence. This has resulted in a slower adoption rate within various healthcare settings, including general care units and outpatient services. For instance, in 2024, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) reaffirmed pregabalin's status as a Schedule 3 medication, which imposes stricter prescription controls and additional record-keeping requirements, further deterring its use among outpatients and primary care providers.

Market Trends of the Global Pregabalin Market

The global pregabalin market is witnessing a robust upward trend, driven by the rising demand for effective neuropathic pain relief solutions. As chronic pain conditions, particularly among aging populations in North America and Europe, become more prevalent, pregabalin, notably branded as Lyrica, has emerged as a go-to therapeutic option for managing ailments such as diabetic neuropathy and post-herpetic neuralgia. To cater to this increasing demand, pharmaceutical companies are innovating by introducing specialized dosage and long-acting formulations. Notably, Pfizer has enhanced its Lyrica CR line with a new formulation specifically designed for geriatric patients, addressing crucial issues of tolerability and compliance, further propelling market growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Pregabalin Market Size by Forms & CAGR (2025-2032)

• Market Overview
• Oral Capsule
• Oral Solution
• Oral Tablet
• Extended Release

Global Pregabalin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Epilepsy
• Neuropathic Pain
• Anxiety Disorder
• Others

Global Pregabalin Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Fibromyalgia Agents
• Anticonvulsants
• Others

Global Pregabalin Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Pregabalin Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Pregabalin Market Size & CAGR (2025-2032)

• North America (Forms, Application, Drug Class, Distribution Channel, End User)
  • US
  • Canada
• Europe (Forms, Application, Drug Class, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Forms, Application, Drug Class, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Forms, Application, Drug Class, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Forms, Application, Drug Class, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals LLC. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medley Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genesisbiotec (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomax Biotechnics (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations